Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Actavis

5 stories about Actavis

Allergan Says Teva Bears Sole Liability for Actavis' Actions
02.09.19|Hezi SternlichtActavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
The Crucial Piece of Information Teva Overlooked
24.12.17|Sophie ShulmanWhen Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17|Uri Tal-TenneThe cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Allergan Sketches Road Show to Sell Teva Stake
14.08.17|Golan HazaniThe company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
Allergan Can Now Sell 9.8% Teva Stake
03.08.17|Dror ReichYesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended

About CTech Terms of Use Privacy Policy

Back to Top